This site supplies research compounds for laboratory use only. You must be 21 years of age or older to enter.
By entering you confirm you are 21+ and agree to our Terms of Service. Products are for research use only — not for human consumption.
metabolic-research
Research Use OnlyRetatrutide is a synthetic peptide characterized in pre-clinical and clinical literature as a triple agonist at the GIP, GLP-1, and glucagon receptors. Investigated for its multi-receptor incretin and glucagon signaling action. Sold for laboratory research and identification purposes only. Not for human consumption.
Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Quantity
Free shipping over $500
Paying by Zelle / Apple Cash
New to sending payment this way? It's quick, and your order is protected:
If we ever can't fulfill your order, you're refunded within 1–2 business days.
Retatrutide
$254
Technical Data
Quality Assurance
Certificate of Analysis
Verified Feedback
2 verified reviews
2 reviews
Easy to order and complete purchase. I have been ordering from them since January 2026 and have received every order on time with no issues. The products are verifiably third party tested and work as they should.
Very good. Great products. Turnaround time was just a tad slow.
Research Overview
Retatrutide (LY3437943) is a synthetic peptide engineered to simultaneously engage three metabolic receptor systems: GIP, GLP-1, and glucagon. The addition of glucagon receptor agonism to the dual-incretin framework introduces thermogenic and lipolytic mechanisms — glucagon signaling drives hepatic fat oxidation, increases energy expenditure, and promotes glycogenolysis — potentially amplifying weight reduction beyond what dual agonists achieve.
The tripartite mechanism is designed for complementary metabolic coverage: GLP-1 agonism suppresses appetite and slows gastric transit; GIP agonism modulates adipose metabolism and enhances insulin sensitivity; glucagon agonism increases basal energy expenditure and accelerates hepatic lipid clearance. Phase 2 clinical data have reported mean body weight reductions of 17–24% at higher doses, the largest treatment effects documented for any single pharmacological agent in obesity research.
ROEHN provides retatrutide at 99% HPLC-verified purity. As one of the most significant emerging compounds in metabolic peptide science, it is under active investigation for applications spanning metabolic-associated steatohepatitis (MASH), cardiovascular risk reduction, and preservation of lean mass during weight loss protocols.
